Literature DB >> 15845370

Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality.

Jason Chesney1, Sucheta Telang, Abdullah Yalcin, Amy Clem, Natalie Wallis, Richard Bucala.   

Abstract

Inducible 6-phosphofructo-2-kinase (iPFK-2; PFKFB3) produces fructose-2,6-bisphosphate (F2,6BP), which is a potent allosteric activator of 6-phosphofructo-1-kinase (PFK-1), the rate-limiting step in glycolysis. iPFK-2 functions as an activator of anaerobic glycolysis within the hypoxic microenvironment of growing tumors. The early embryo is challenged similarly since the process of vasculogenesis does not begin until after embryonic day 7. We hypothesized that iPFK-2 expression is essential for the survival of the growing embryo. First, we cloned the mouse homolog of iPFK2 and found that it is abundantly expressed in cortical neurons, epithelial cells, and secretory cells of the choroid plexus, pancreas, and adrenal gland of the adult mouse. Using gene targeting, we then disrupted exons 3-7 of the mouse iPFK2 gene, which encode the substrate binding site. No full-term homozygous iPFK-2(-/-) progeny were produced from 11 F7 iPFK-2(+/-) crosses and no homozygous iPFK-2(-/-) embryos were detected after 8 days of embryogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845370     DOI: 10.1016/j.bbrc.2005.02.193

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3: transition state and the C-terminal function.

Authors:  Michael C Cavalier; Song-Gun Kim; David Neau; Yong-Hwan Lee
Journal:  Proteins       Date:  2012-01-31

2.  Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.

Authors:  Xiaoli Li; Jian Liu; Li Qian; Honggang Ke; Chan Yao; Wei Tian; Yifei Liu; Jianguo Zhang
Journal:  Mol Cell Biochem       Date:  2018-01-11       Impact factor: 3.396

Review 3.  The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction.

Authors:  Maria M Szwarc; Ramakrishna Kommagani; Bruce A Lessey; John P Lydon
Journal:  Biol Reprod       Date:  2014-10-08       Impact factor: 4.285

4.  Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.

Authors:  Xin Guo; Kefeng Xu; Jifeng Zhang; Honggui Li; Weiyu Zhang; Huan Wang; Alex J Lange; Y Eugene Chen; Yuqing Huo; Chaodong Wu
Journal:  J Biol Chem       Date:  2010-05-24       Impact factor: 5.157

5.  PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension.

Authors:  Yapeng Cao; Xiaoyu Zhang; Lina Wang; Qiuhua Yang; Qian Ma; Jiean Xu; Jingjing Wang; Laszlo Kovacs; Ramon J Ayon; Zhiping Liu; Min Zhang; Yaqi Zhou; Xianqiu Zeng; Yiming Xu; Yong Wang; David J Fulton; Neal L Weintraub; Rudolf Lucas; Zheng Dong; Jason X-J Yuan; Jennifer C Sullivan; Louise Meadows; Scott A Barman; Chaodong Wu; Junmin Quan; Mei Hong; Yunchao Su; Yuqing Huo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

6.  Inhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.

Authors:  Yaoyao Zou; Shan Zeng; Mingcheng Huang; Qian Qiu; Youjun Xiao; Maohua Shi; Zhongping Zhan; Liuqin Liang; Xiuyan Yang; Hanshi Xu
Journal:  Br J Pharmacol       Date:  2017-03-27       Impact factor: 8.739

7.  Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.

Authors:  Xin Guo; Honggui Li; Hang Xu; Vera Halim; Laura N Thomas; Shih-Lung Woo; Yuqing Huo; Y Eugene Chen; Joseph M Sturino; Chaodong Wu
Journal:  J Nutr Biochem       Date:  2012-07-26       Impact factor: 6.048

8.  Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.

Authors:  Yuqing Huo; Xin Guo; Honggui Li; Huan Wang; Weiyu Zhang; Ying Wang; Huaijun Zhou; Zhanguo Gao; Sucheta Telang; Jason Chesney; Y Eugene Chen; Jianping Ye; Robert S Chapkin; Chaodong Wu
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

9.  Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Authors:  Brian F Clem; Julie O'Neal; Gilles Tapolsky; Amy L Clem; Yoannis Imbert-Fernandez; Daniel A Kerr; Alden C Klarer; Rebecca Redman; Donald M Miller; John O Trent; Sucheta Telang; Jason Chesney
Journal:  Mol Cancer Ther       Date:  2013-05-14       Impact factor: 6.261

10.  Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.

Authors:  Sucheta Telang; Brian F Clem; Alden C Klarer; Amy L Clem; John O Trent; Richard Bucala; Jason Chesney
Journal:  J Transl Med       Date:  2012-05-16       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.